TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs
Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the presence of Trk fusion, regardless of cancer type...
Gorde:
| Egile nagusia: | |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI AG
2021-06-01
|
| Saila: | Pharmaceuticals |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.mdpi.com/1424-8247/14/7/632 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|